scholarly journals Postmenopausal Iron Overload Exacerbated Bone Loss by Promoting the Degradation of Type I Collagen

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Qian Cheng ◽  
Xiaofei Zhang ◽  
Jun Jiang ◽  
Guoyang Zhao ◽  
Yin Wang ◽  
...  
Keyword(s):  
Bone Loss ◽  
Iron Overload ◽  
Postmenopausal Women ◽  
Serum Ferritin ◽  
Type I Collagen ◽  
Degradation Products ◽  
Normal Group ◽  
Type I ◽  
Positive Correlation ◽  
Normal Bone

117 postmenopausal women were divided into Normal, Bone loss (BL), and Osteoporosis group. Compared with Normal group (120.96 ± 43.18 μg/L), the serum ferritin (Fer) in BL (223.37 ± 130.27 μg/L) and Osteoporosis group (307.50 ± 161.48 μg/L) was significantly increased (p < 0.05). Fer level was negatively correlated with BMD (p < 0.01). TRACP levels in Osteoporosis group (4.37 ± 1.69 U/L) were significantly higher than Normal group (4.10 ± 1.60 U/L, p < 0.05). ALP levels in Osteoporosis group (112.06 ± 62.05 U/L) were significantly upregulated compared with Normal group (80.22 ± 14.94 U/L, p < 0.05). β-CTX and PINP were the degradation products of type I collagen. β-CTX levels in Osteoporosis group (667.90 ± 316.55 ng/L) were significantly increased compared with Normal group (406.06 ± 112.12 ng/L, p < 0.05). PINP levels in Osteoporosis group (78.03 ± 37.31 μg/L) were significantly higher than Normal group (37.60 ± 13.17 μg/L, p < 0.01). More importantly, there was a positive correlation between serum Fer and PINP (p < 0.01). Serum Fer showed a positive correlation of serum β-CTX (p < 0.01). The overloaded iron improved the degradation of type I collagen.

scholarly journals Inhibition of bone turnover by milk intake in postmenopausal women

2008 ◽  
Vol 100 (4) ◽  
pp. 866-874 ◽  
Author(s):  
Jean-Philippe Bonjour ◽  
Marion Brandolini-Bunlon ◽  
Yves Boirie ◽  
Françoise Morel-Laporte ◽  
Véronique Braesco ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Bone Loss ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Type I Collagen ◽  
Hormone Secretion ◽  
Type I ◽  
Type I Procollagen ◽  
Prevention Of Osteoporosis ◽  
Skimmed Milk

Increased postmenopausal bone turnover leads to bone loss and fragility fracture risk. In the absence of osteoporosis, risk preventive measures, particularly those modifying nutritional lifestyle, are appropriate. We tested the hypothesis that milk supplementation affects bone turnover related to biochemical markers in a direction that, in the long term, may be expected to reduce postmenopausal bone loss. Thirty healthy postmenopausal women aged 59·3 (sd3·3) years were enrolled in a prospective crossover trial of 16 weeks. After a 4-week period of adaptation with diet providing 600 mg calcium plus 300 mg ingested as 250 ml semi-skimmed milk, participants were maintained during 6 weeks under the same 600 mg calcium diet and randomized to receive either 500 ml semi-skimmed milk, thus providing a total of 1200 mg calcium, or no milk supplement. In the next 6 weeks they were switched to the alternative regimen. At the end of the each period, i.e. after 4, 10 and 16 weeks, blood and urinary samples were collected. The changes in blood variables between the periods of 6 weeks without and with milk supplementation were: for parathyroid hormone, − 3·2 pg/ml (P = 0·0054); for crosslinked telopeptide of type I collagen, − 624 pg/ml (P < 0·0001); for propeptide of type I procollagen, − 5·5 ng/ml (P = 0·0092); for osteocalcin, − 2·8 ng/ml (P = 0·0014). In conclusion, a 6-week period of milk supplementation induced a decrease in several biochemical variables compatible with diminished bone turnover mediated by reduction in parathyroid hormone secretion. This nutritional approach to postmenopausal alteration in bone metabolism may be a valuable measure in the primary prevention of osteoporosis.

scholarly journals Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen

1998 ◽  
Vol 44 (11) ◽  
pp. 2281-2289 ◽  
Author(s):  
Christian Rosenquist ◽  
Christian Fledelius ◽  
Stephan Christgau ◽  
Brian J Pedersen ◽  
Martin Bonde ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Postmenopausal Women ◽  
Type I Collagen ◽  
Degradation Products ◽  
Hormone Replacement ◽  
Premenopausal Women ◽  
Type I ◽  
Serum Samples ◽  
Aspartic Acid Residue ◽  
One Step

Abstract We have developed a two-site ELISA for measurement in serum of bone-related degradation products derived from C-terminal telopeptides of type I collagen. The assay is based on the application of two highly specific monoclonal antibodies against the amino acid sequence of AHD-β-GGR, where the aspartic acid residue (D) is β-isomerized. In a one-step incubation procedure, the degradation products containing cross-linked diisomerized EKAHD-β-GGR peptides are captured by a biotinylated antibody and a peroxidase-conjugated antibody. The generated complex is then bound to the streptavidin surface via the biotin conjugate. Desalted urinary antigens are used for standardization, and parallelism is observed with serum samples. Results are obtained in &lt;2.5 h, and both inter- and intraassay imprecision are &lt;8%. The serum CrossLaps™ concentration was 1748 ± 740 pmol/L (mean ± SD) in premenopausal women (n = 65) and 2952 ± 1325 pmol/L in a group of healthy postmenopausal women (n = 169). The Serum CrossLaps One Step ELISA was capable of detecting a highly significant (P &lt;0.001) effect of hormone replacement therapy in a retrospective study involving 22 postmenopausal women.

scholarly journals Increased Sclerostin Serum Levels Associated with Bone Formation and Resorption Markers in Patients with Immobilization-Induced Bone Loss

2010 ◽  
Vol 95 (5) ◽  
pp. 2248-2253 ◽  
Author(s):  
Agostino Gaudio ◽  
Pietra Pennisi ◽  
Cornelia Bratengeier ◽  
Venerando Torrisi ◽  
Brigitte Lindner ◽  
...  
Keyword(s):  
Bone Loss ◽  
Bone Formation ◽  
Postmenopausal Women ◽  
Quantitative Ultrasound ◽  
Type I Collagen ◽  
Mechanical Strain ◽  
Serum Levels ◽  
Type I ◽  
Ultrasound Measurements ◽  
Dickkopf 1

Abstract Context: Sclerostin, a Wnt signaling antagonist on the osteoblasts produced by osteocytes, is regulated by mechanical strain and is implicated in the pathogenesis of disuse bone loss. There are no data on sclerostin in humans. Objective: The aim of the study was to evaluate sclerostin in patients immobilized after stroke, compared with control subjects, and to analyze its relationship with markers of bone formation and resorption. Design: This was a cross-sectional study. Setting and patients: We studied 40 postmenopausal women immobilized after a single episode of stroke 6 months or longer after onset, and 40 postmenopausal women from the general community. Bone status was assessed by quantitative ultrasound measurements at the calcaneus. Bone alkaline phosphatase (b-AP), carboxy-terminal telopeptide of type I collagen (CrossLaps), and sclerostin were evaluated by ELISA. We also used ELISA to measure serum levels of Dickkopf-1, another soluble inhibitor of Wnt/β-catenin signaling, highly expressed by osteocytes. Results: Immobilized patients had higher sclerostin serum levels (median 0.975 ng/ml; 25th to 75th percentiles 0.662–1.490) than controls (median 0.300 ng/ml; 25th to 75th percentiles 0.165–0.400: P &lt; 0.0001) and an increased bone turnover with a more significant rise in bone resorption (CrossLaps) than formation (b-AP) markers. Sclerostin correlated negatively with b-AP (r = −0.911; P &lt; 0.0001) and positively with CrossLaps (r = 0.391; P = 0.012). Dickkopf-1 did not significantly differ between the groups. Patients also had quantitative ultrasound measurements index lower than controls (P &lt; 0.001). Conclusions: This study shows for the first time that long-term immobilized patients present hypersclerostinemia associated with reduced bone formation, and suggests that sclerostin could be a link between mechanical unloading and disuse osteoporosis in humans.

scholarly journals Evaluation of a Fully Automated Serum Assay for C-Terminal Cross-Linking Telopeptide of Type I Collagen in Osteoporosis

2001 ◽  
Vol 47 (4) ◽  
pp. 694-702 ◽  
Author(s):  
Patrick Garnero ◽  
Olivier Borel ◽  
Pierre D Delmas
Keyword(s):  
Bone Resorption ◽  
Bone Loss ◽  
Postmenopausal Women ◽  
Type I Collagen ◽  
Premenopausal Women ◽  
Cross Linking ◽  
Type I ◽  
Baseline Serum ◽  
Healthy Women ◽  
Automated Assay

Abstract Background: Biochemical markers of bone turnover can provide prognostic information about the risk of osteoporotic fracture and are useful tools for monitoring efficacy of antiresorptive therapy. A serum-based automated assay may be of better clinical value than urinary markers because of lower imprecision and day-to-day within-person variability. Our aim was to evaluate the technical and clinical performances of a new, fully automated assay for serum C-terminal cross-linking telopeptide of type I collagen (CTX), a marker of bone resorption. Methods: Serum CTX was measured on the Elecsys 2010 automated analyzer (Roche). Results were compared with those of the manual ELISA. We measured serum CTX concentrations in 728 healthy women, ages 31–89 years. We investigated the ability of this assay to predict the rate of postmenopausal forearm bone loss evaluated by four repeated bone mineral density measurements using dual-x-ray absorptiometry in 305 women followed prospectively for 4 years. Finally, in a cohort of healthy, untreated, postmenopausal women, we compared baseline serum CTX in 55 women who subsequently had a fracture (20 vertebral and 35 peripheral fractures) with values in the 380 women who did not fracture during a mean 5 years of follow-up. Results: The within- (n = 21) and between-run (n = 21) CVs were &lt;4.1% and 5.7%, respectively. In 728 healthy women, serum CTX concentrations (automated) correlated with those of the manual ELISA (r = 0.82; P &lt;0.0001). The median long-term within-person variability assessed by four repeated measurements over 3 months in 18 postmenopausal women was 9.4%. Compared with 254 premenopausal women, serum CTX was 39% (P &lt;0.0001) higher in 45 perimenopausal women and 86% (P &lt;0.0001) higher in 429 postmenopausal women (mean age, 64 years). Baseline serum CTX correlated negatively with changes of bone mass measured at the mid (r = −0.23; P &lt;0.0001) and distal (r = −0.27; P &lt;0001) radius. Postmenopausal women with serum CTX greater than the mean + 2 SD values in premenopausal women accounted for 42% of the population, lost bone at the mid radius on average eightfold more rapidly than the other women (−0.27% ± 2.92% vs −2.25% ± 3.95%; P &lt;0.0001), and had increased risk of fracture with a relative risk (95% confidence interval) of 1.8 (1.01–3.1) after adjustment for physical activity. Conclusions: The automated assay for serum CTX is precise and predicts rate of bone loss and fracture risk in postmenopausal women. Because it is convenient to use and has high throughput, this serum bone resorption marker may be useful for the investigation of patients with osteoporosis.

Diurnal variation in concentrations of various markers of bone metabolism in growing female goats and sheep

2003 ◽  
Vol 77 (2) ◽  
pp. 197-203 ◽  
Author(s):  
A. Liesegang ◽  
M.-L. Sassi ◽  
J. Risteli
Keyword(s):  
Type I Collagen ◽  
Bone Markers ◽  
Degradation Products ◽  
Bone Marker ◽  
Type I ◽  
Blood Samples ◽  
Bone Specific Alkaline Phosphatase ◽  
Growing Goats ◽  
Turn Over ◽  
Carboxyterminal Telopeptide

AbstractTwelve 6-month-old growing female goats and sheep were used in this study. Blood samples were obtained in the morning before goats and sheep were given food and then at 2-h intervals for 24 h (part I). This procedure was repeated 2 weeks later (part II). Concentrations of osteocalcin (OC), activities of total (tAP) and bone-specific alkaline phosphatase (bAP), degradation products of C-terminal telopeptide of type-I collagen (CrossLaps™ CL), and carboxyterminal telopeptide of type-I collagen (ICTP) were measured in serum.In both parts of the study, all bone marker concentrations were significantly higher in goats than in sheep. The OC concentrations in goats increased in the late afternoon/evening and decreased thereafter to reach values similar to those obtained at the beginning. The ICTP concentrations in goats slowly decreased until 14:00 h, increased, and decreased again. The concentrations in sheep decreased continuously but not significantly, towards the morning sampling. The CL concentrations increased in both sheep and goats during the night but at 06:00 h started to decrease to levels found at the beginning of testing. The bAP activities decreased in goats from 20:00 to 22:00 h. Changes in the concentrations of bone markers were mainly observed in goats of this study. As documented for bone resorption and formation in other species, circadian rhythms were evident for concentrations of ICTP, CL, bAP and OC. The present study indicates that growing goats may have a physiologically higher bone turn-over than growing sheep, because the bone marker concentrations were always higher.

scholarly journals Coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption

1996 ◽  
Vol 42 (10) ◽  
pp. 1639-1644 ◽  
Author(s):  
M Bonde ◽  
C Fledelius ◽  
P Qvist ◽  
C Christiansen
Keyword(s):  
Bone Resorption ◽  
Postmenopausal Women ◽  
Type I Collagen ◽  
Premenopausal Women ◽  
Type I ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Analytical Recovery ◽  
Controlled Clinical Study ◽  
Different Doses

Abstract We present a coated-tube RIA that is useful for assessment of bone resorption. The assay uses a monoclonal antibody raised against a linear 8-amino-acid sequence (EKAHDGGR) derived from the C-telopeptides of type I collagen. Within-run and total CVs were 4.4% and 5.3-6.2%, respectively, at concentrations of 1-7 mg/L (n = 4-20). Analytical recovery was 98% +/- 8% and dilution 97% +/- 7%. Values obtained in a group of 36 premenopausal women were 227 +/- 89.6 mg/mol creatinine. In a group of 141 postmenopausal women, the values obtained were 429 +/- 225 mg/mol creatinine, a highly significant increase of 89% (P &lt;0.001) over the premenopausal value. In a double-blind placebo-controlled clinical study of these postmenopausal women receiving five different doses of a bisphosphonate, a significant decrease of RIA-measured C-telopeptide values was seen in all bisphosphonate-treated groups, after just 3 months. Values in urine samples from postmenopausal women assayed with the RIA (gamma) and the CrossLaps(TM) ELISA (x) agreed well: slope = 0.98 (95% confidence interval, 0.94-1.01), intercept = 0.34 (0.25-0.43) mg/L, and Sylx = 0.93 mg/L (n = 678). We conclude that this RIA represents a valuable tool for assessing bone resorption.

Immunoassay for quantifying type I collagen degradation products in urine evaluated

1994 ◽  
Vol 40 (11) ◽  
pp. 2022-2025 ◽  
Author(s):  
M Bonde ◽  
P Qvist ◽  
C Fledelius ◽  
B J Riis ◽  
C Christiansen
Keyword(s):  
Type I Collagen ◽  
Degradation Products ◽  
Mean Value ◽  
Collagen Degradation ◽  
Enzyme Linked Immunosorbent Assay ◽  
Bone Resorption Marker ◽  
Type I ◽  
Analytical Recovery ◽  
Collagen Degradation Products ◽  
Better Than

Abstract An enzyme-linked immunosorbent assay (ELISA) for measuring type I collagen degradation products in urine &lt; 3 h was evaluated. The measuring range was 0.5-10.5 mg/L with a detection limit of 0.2 mg/L. Within-run and total CVs were 5.3% and 6.6%, respectively. Analytical recovery averaged 100%. The mean (+/- SD) concentrations in urine samples from a healthy premenopausal population (n = 102) were 250 +/- 110 mg/mol creatinine (Cr). A group of healthy postmenopausal women (n = 410) gave a mean value of 416 +/- 189 mg/mol Cr. Values obtained in the ELISA correlated well (r = 0.83) to HPLC values for the established bone resorption marker deoxypyridinoline (n = 214), slightly better than the correlation to hydroxyproline measurements (r = 0.78, n = 421). We conclude that the assay described here presents a useful tool for further elucidating the importance of type I collagen degradation products in urine.

scholarly journals Effect of BMI(Body Mass Index) on BMD (Bone Mineral Density) in Postmenopausal Women

2020 ◽  
Vol 28 (1) ◽  
pp. 60-66
Author(s):  
Tabassum Ghani ◽  
Subinoy Krishna Paul ◽  
Afrina Begum ◽  
Noorjahan ◽  
Mandira Sarkar ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Body Mass Index ◽  
Bone Loss ◽  
Postmenopausal Women ◽  
Body Mass ◽  
Bone Mineral ◽  
Significant Positive Correlation ◽  
Mineral Density ◽  
Positive Correlation ◽  
Medical College

Menopause is commonly associated with rapid bone loss and this bone loss manifests as a significant decrease in bone mineral density (BMD). Body weight or body mass index is the most important factor which influences BMD. Aim of this study was to evaluate the association between BMI and BMD in post menopausal women. Also to measure the correlation between age, duration of menopause, weight with BMD. This cross-sectional study was undertaken in the Department of Obstetrics and Gynaecology in Dhaka Medical College Hospital, Dhaka from January, 2012 to December, 2012. The study included women of 50 to 70 years who had menopause with three or more parity. Total 100 women were evaluated by history taking, physical examination and laboratory investigation (BMD).The results showed that there was significant positive correlation between BMI and BMD value of L1-4 and total femur (Pearson‘s coefficient was +0.285, P<0.01 and +.350, P<.001). There was also significant positive correlation between weight and T- score of L1-4 (r =+ .482, P<.01) and Total femur (r = +.513, P< .01). In addition, significant negative correlation was found between BMD with age and duration of menopause. It can be concluded that in postmenopausal women as the BMI decreases bone mineral density also decreases. So, adequate weight and BMI necessary for the prevention of osteoporosis. J Dhaka Medical College, Vol. 28, No.1, April, 2019, Page 60-66

Sign in / Sign up

Export Citation Format

Share Document